GENFIT S.A EPS - Earnings per Share 2019-2021 | GNFT
GENFIT S.A eps - earnings per share from 2019 to 2021. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| GENFIT S.A Annual EPS |
| 2021 |
$1.46 |
| 2020 |
$-2.97 |
| 2019 |
$-1.97 |
| 2018 |
$-3.01 |
| GENFIT S.A Quarterly EPS |
| 2021-12-31 |
$0.00 |
| 2021-06-30 |
$0.00 |
| 2020-12-31 |
$0.00 |
| 2020-06-30 |
$0.00 |
| 2019-12-31 |
$0.00 |
| 2019-06-30 |
$0.00 |
| 2018-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.170B |
$0.101B |
|
Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company's lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France.
|
